Tag Archives: PDT

Transient fluid flow improves photoimmunoconjugate delivery and photoimmunotherapy efficacy

June 26, 2023 by Modulight Content
No comments
Published in: iScience Authors: Aaron J. Sorrin, Keri Zhou, Katherine May, Cindy Liu, Kathryn McNaughton, Idrisa Rahman, Barry J. Liang, Imran Rizvi, Dana M. Roque, Huang-Chiao Huang    Published in: iScience Authors: Aaron J. Sorrin, Keri Zhou, Katherine May, Cindy Liu, Kathryn McNaughton, Idrisa Rahman, Barry J. Liang, Imran Rizvi, Dana M. Roque, Huang-Chiao Huang   The study showed that fluid flow induced shear stress increased the photocytotoxicity of different photosensitizers tested (BPD, PIC, PIC-coated liposome) against ovarian cancer cells. The cellular delivery of photosensitizers doubled compared to static conditions. Modulight laser was used for PDT activation together with photosensitizer(s). Circulating drugs in the peritoneal cavity is an effective strategy for advanced ovarian Continue reading →

Fluorescence-guided, targeted photochemotherapy of peritoneal carcinomatosis

March 17, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Barry J. Liang, Robert Perttilä, Sumiao Pang, Chen-Hua Ma, Payal Srivastava, Brandon Gaitan, Aaron J. Sorrin, Zoe Ylöniemi, Dana Roque, Tayyaba Hasan, Petteri Uusimaa, Huang-Chiao Huang    Presented in: SPIE BIOS 2023 Authors: Barry J. Liang, Robert Perttilä, Sumiao Pang, Chen-Hua Ma, Payal Srivastava, Brandon Gaitan, Aaron J. Sorrin, Zoe Ylöniemi, Dana Roque, Tayyaba Hasan, Petteri Uusimaa, Huang-Chiao Huang   Management of peritoneally metastatic cancer is a major clinical challenge. Peritoneal carcinomatosis is observed in 50% of colorectal cancer patients and >75% of ovarian cancer patients at the time of diagnosis. Selected patients based on age, comorbidities, and extent of the metastatic disease, will undergo complete cytoreductive surgery to remove the visible Continue reading →

Laser platform and light delivery optimization for bladder cancer treatment with a novel photosensitive drug

March 14, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Zoe Ylöniemi, Elias Kokko, Visa Kaivosoja, Ana Colucci, Eerika Suokas, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Zoe Ylöniemi, Elias Kokko, Visa Kaivosoja, Ana Colucci, Eerika Suokas, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.   Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a relatively high 5-year survival rate but also very high recurrence rate. Photodynamic diagnosis is commonly used in standard clinical practice to visualize bladder cancer lesions as part of a TURBT procedure but photodynamic treatments utilizing photosensitive drugs have had limited success in clinical setting partly because of limitations in light Continue reading →

Novel ophthalmic PDT laser platform to target oncology and various other retinal indications

March 14, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Eero Koivumäki, Jukka-Pekka Alanko, Timo Tanila, Ivan Baldin, Zoe Ylöniemi, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Laura Vesala, Eero Koivumäki, Jukka-Pekka Alanko, Timo Tanila, Ivan Baldin, Zoe Ylöniemi, Petteri Uusimaa, Modulight Corp.   Laser systems, in ophthalmic applications, are utilized in the treatment of various ophthalmic diseases such as in ocular oncology and age-related macular degeneration through photochemical mechanism of photodynamic therapy. In addition, these lasers can be used to activate drug delivery systems in the retina to provide targeted drug therapy. PDT is a form of a combination treatment which utilizes light energy to Continue reading →

Optimization of light delivery for non-muscle invasive bladder cancer PDT

March 14, 2023 by Modulight Content
No comments
Presented in: SPIE BIOS 2023 Authors: Elias Kokko, Robert Perttilä, Zoe Ylöniemi, Visa Kaivosoja, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.    Presented in: SPIE BIOS 2023 Authors: Elias Kokko, Robert Perttilä, Zoe Ylöniemi, Visa Kaivosoja, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.   Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a relatively high 5-year survival rate but also very high recurrence rate. Photodynamic diagnosis is commonly used in standard clinical practice to visualize bladder cancer lesions as part of a TURBT procedure but photodynamic treatments utilizing photosensitive drugs have had limited success in clinical setting partly because of limitations in light sources and Continue reading →

A Non-Invasive Deep Photoablation Technique to Inhibit DCIS Progression and Induce Antitumor Immunity

November 23, 2022 by Modulight Content
No comments
Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada    Published in: Cancers Authors: Kensuke Kaneko, Hiroshi Nagata, Xiao-Yi Yang, Joshua Ginzel, Zachary Hartman, Jeffrey Everitt, Philip Hughes, Timothy Haystead, Michael Morse, Herbert Kim Lyerly, Takuya Osada   The study investigated HSP90-targeted PDT for minimally invasive treatment of ductal carcinoma in situ (DCIS), benign breast cancer condition that has potential to progress into breast cancer. PDT with ML8500 combined to ML7710 resulted in effective in vitro cytotoxicity and with ML7710 in vivo, which was further potentiated with PD-L1 immune checkpoint inhibitors.   Read the article Continue reading →

Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers

September 28, 2022 by Modulight Content
No comments
Published in: Journal for ImmunoTherapy of Cancer Authors: Kensuke Kaneko, Chaitanya R Acharya, Hiroshi Nagata, Xiao Yang, Zachary Conrad Hartman, Amy Hobeika, Philip F Hughes, Timothy A J Haystead, Michael A Morse, Herbert Kim Lyerly, Takuya Osada    Published in: Journal for ImmunoTherapy of Cancer Authors: Kensuke Kaneko, Chaitanya R Acharya, Hiroshi Nagata, Xiao Yang, Zachary Conrad Hartman, Amy Hobeika, Philip F Hughes, Timothy A J Haystead, Michael A Morse, Herbert Kim Lyerly, Takuya Osada   Heat shock protein (HS291) targeted PDT was studied in mice with ML7710 to understand immunological component and combination with immune checkpoint inhibitors. The study demonstrates the potential of combined Hsp90-targeted PDT and PD-1/PD-L1 blockade in breast cancer immunotherapy and abscopal effect i.e. efficacy on distal tumors.   Continue reading →

Pharmaceutical nanotechnology applied to phthalocyanines for the promotion of antimicrobial photodynamic therapy: A literature review

September 1, 2022 by Modulight Content
No comments
Published in: Photodiagnosis and Photodynamic Therapy Authors: Luciana Betzler de Oliveira de Siqueira, Ana Paula dos Santos Matos, Marcio Robert Mattos da Silva, Suvene Rocha Pinto, Ralph Santos-Oliveira, Eduardo Ricci-Júnior  Published in: Photodiagnosis and Photodynamic Therapy Authors: Luciana Betzler de Oliveira de Siqueira, Ana Paula dos Santos Matos, Marcio Robert Mattos da Silva, Suvene Rocha Pinto, Ralph Santos-Oliveira, Eduardo Ricci-Júnior   Phthalocyanines are photosensitizers activated by light at a specific wavelength in the presence of oxygen and act through the production of Reactive Oxygen Species, which simultaneously attack several biomolecular targets in the pathogen agent and, therefore, have multiple and variable action sites. This nonspecific action site bypasses conventional resistance mechanisms. Antimicrobial Photodynamic Therapy (aPDT) is Continue reading →

Optimizing photosensitizer administration for cancer therapy

December 11, 2021 by Modulight Content
No comments
  Motivation While Photofrin PDT is an approved oncological therapy for multiple indications, its wider use is hindered by prolonged skin photosensitivity lasting several weeks. The aim of this study is to investigate intratumoral Photofrin administration as a way to decrease skin photosensitivity compared to the standard IV injection protocol. Tumor necrosis after PDT was assessed with immunohistochemical staining and Photofrin distributions by fluorescence microscopy.       Results   Anti-tumor efficacy was similar between intratumoral and IV administration; however, smaller doses of Photofrin were Continue reading →Customer case University of Rochester belongs among the nation’s top research universities. Research at the Baran lab focuses on anti-microbial PDT and optical image processing. The aim is to develop methods for utilizing quantitative information from CT, MR and PET imaging for PDT treatment planning as well as in the search of new biomarkers and therapeutic targets. Modulight products: ML7710 (630 & 665 nm) Link to the study: Timothy M. Baran (Ph.D., PI) Laser use: Ongoing clinical Phase 1 safety & feasibility study for methylene Continue reading →

Light penetration depth in brain with different photosensitizers

October 28, 2021 by Modulight Content
No comments
  Motivation for the study Glioblastoma is the most aggressive and lethal brain cancer with an average prognosis of 15 months. Fluorescence-guided surgery (FGS) for glioblastoma was FDA-approved in 2017, while photodynamic therapy (PDT) remains an active area of clinical investigation with very promising results so far. The aim of PDT is to eradicate the invasive cancer cells within 2 cm of the resected area where the glioblastoma most often recurs. However, a significant hurdle of this therapy modality is the limited light penetration depth Continue reading →Customer case Research by: University of Maryland, Optical Therapeutics & Nanotechnology Laboratory led by Prof. Huang. Research focuses on precision cancer nanomedicine, drug delivery strategies, overcoming cancer resistance, mechanism-based combination therapies, site-directed photochemistry and fluorescence diagnostics. Modulight has started a joint R&D program with Dr. Huang lab to study novel EGFR-targeted combination therapy/diagnostic agent PIC-Nal-IRI developed by Huang lab. Modulight products: ML6600 laser system (635 nm and 689 nm). Professor Huang-Chiao Huang Laser use: Targeted photodynamic therapy/photoimmunotherapy with benzoporphyrin derivative (BPD) & 5-aminolevulinic acid (5-ALA) photosensitizers. Continue reading →